2 results about "Morpholino Oligos" patented technology

Described herein are methods and compositions for treating solid or liquid B-cell malignancies using a two-component platform based on morpholino oligonucleotide-linked conjugates to target B-cells and effector cells. The methods described herein may involve two distinct dosing approaches tailored to the type of B-cell malignancy being treated. In some embodiments, solid B-cell tumors are treated using a premixed assembly dosing regimen. In some embodiments, liquid B-cell tumors are treated using a consecutive dosing regimen.

The application provides a chiral morpholino phosphorus oxychloride monomer and a preparation method and application thereof, and the structure of the monomer is shown in formula I or II: wherein X represents an oxygen atom or a sulfur atom; B represents a base; R 1 is selected from an optionally substituted secondary substituted amine group, an optionally substituted alkoxy group, an optionally substituted phenoxy group, a guanidino group, and a linked nitrogen forming an optionally substituted heterocyclic ring; R 2 is selected from an optionally substituted or unsubstituted tertiary alkyl group, an optionally substituted or unsubstituted benzyl group, an optionally substituted sulfonyl group, and an optionally substituted acyl group. The application can obtain the chiral morpholino phosphorus oxychloride monomer in a stereochemically pure or substantially pure form by using an efficient catalytic asymmetric desymmetrization strategy. And the corresponding morpholino oligonucleotide chain can be synthesized based on the monomer, thereby providing a powerful synthesis platform for developing a new generation of morpholino oligonucleotide drugs with precise stereostructure and optimized performance.